DOI:
10.1055/s-00000029
Journal of Reconstructive Microsurgery
LinksClose Window
References
Lancet T. ; ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy.
Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.
Lancet 2000;
356 (9247): 2037-2044
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.